Sanofi to Help Manufacture Moderna COVID-19 Vaccine in the U.S.
Sanofi has partnered with Moderna to help manufacture up to 200 million doses of Moderna’s COVID-19 vaccine at its plant in Ridgefield, N.J., for U.S. distribution beginning in September.
Moderna’s two-dose vaccine, mRNA-1273, has proved to be more than 95 percent effective in preventing severe COVID-19 infections and the company is currently committed to supplying 200 million doses to the U.S. by the end of July.
The deal marks Sanofi’s third coronavirus vaccine manufacturing pact. The French drugmaker previously announced an agreement with BioNTech to help produce 125 million doses of its vaccine co-developed with Pfizer, and another with Johnson & Johnson (J&J) to assist in the manufacture of an estimated 12 million J&J vaccine doses per month.